Mobile

A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9 μg formo...

Update Il y a 4 ans
Reference: EUCTR2009-011265-82

A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9 μg formoterol bid and placebo in patients with moderate to severe COPD

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Primary objective is: • To compare the clinical efficacy of AZD3199 inhaled once daily with 9 μg formoterol twice daily and placebo over a 4-week treatment period in adults with chronic obstructive pulmonary disease (COPD)

Inclusion criteria

  • Chronic Obstructive Pulmonary Disease (COPD)

Links